BC Week In Review | Apr 11, 2011
Clinical News

Tarceva erlotinib: Additional Phase II data

Researchers at the M.D. Anderson Cancer Center reported additional data from a subgroup of 101 stage IV NSCLC patients who had gene expression profiles obtained from pretreatment core needle biopsies in the adaptive, open-label, U.S....
BC Innovations | Sep 23, 2010
Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Immunohistochemical characterization of medulloblastomas based on dickkopf homolog 1 (DKK1), secreted frizzled-related protein 1 (SFRP1), natriuretic peptide receptor C/guanylate cyclase C (NPR3) and potassium channel Kv1.1...
Items per page:
1 - 2 of 2